Shares of Neogenomics rose 1.27% after CareDx agreed to acquire Naveris to expand into high-growth specialty oncology. The deal accelerates consolidation in oncology diagnostics and could intensify competition for Neogenomics’ testing services.
On July 2, CareDx completed the acquisition of Naveris, a specialty oncology diagnostics provider, broadening its portfolio beyond transplant monitoring into immuno-oncology testing solutions. The move aims to capture faster-growing segments within cancer diagnostics and strengthen CareDx’s position in targeted therapy monitoring.
The transaction marks a wave of consolidation in the oncology diagnostics space, creating a larger competitor for Neogenomics in high-value testing services. Increased scale and combined R&D capabilities could put pressure on pricing and margin profiles across peers.
In early trading, Neogenomics shares climbed 1.27% as investors weighed the intensified competition, while CareDx stock slipped 0.21% as the acquisition’s integration costs came into focus. Market participants are watching how peers adjust strategies in response to the deal.
